The Controversial Role of Phosphodiesterase Type 5 Inhibitors in the Treatment of Premature Ejaculation

While it is evident that PDE5is are the first choice in patients with comorbid ED and PE (where one may be secondary to the other), well‐designed studies on the possible use of PDE5is in PE patients without ED are still limited. The issue will be less controversial when further evidence on the role of NO and PDE5 in the mechanism of ejaculation is available. Jannini EA, McMahon C, Chen J, Aversa A, and Perelman M. The controversial role of PDE5 inhibitors in the treatment of premature ejaculation. J Sex Med 2011;8:2135-2143.